New collaboration shifts the focus from slowing liver damage to understanding how scarred tissue may heal itself.
“The global leader in ECM-based drug discovery and development, delivering life-changing therapies to patients with chronic diseases.”
That’s how London-based biotech Engitix describes its mission. This week, the company took a significant step toward that ambition, announcing a strategic collaboration with GSK that could help answer one of medicine’s most frustrating questions: can organ scarring actually be reversed?
For so many years, researchers studying fibrosis have largely focused on slowing damage. The logic was straightforward – if you can stop scar tissue from building up, you might be able to prevent disease from worsening. However, what if the more important question isn’t how damage happens, but how healing happens?
That’s the premise behind the newly announced partnership between Engitix and GSK, which will focus on identifying biological mechanisms linked to liver fibrosis regression, the process by which scarred tissue begins to recover [1].
Fibrosis is often described as scarring, but that simple word doesn’t fully capture what’s happening inside the body. When tissue is injured, the body launches a repair response. In the short term, that’s a good thing. The problem begins when the repair process never properly switches off. In fibrosis, scar tissue accumulates, disrupting the normal architecture and function of an organ.
In the liver, that can have serious consequences. As scar tissue builds up, the organ becomes less effective at carrying out the countless tasks that keep the body functioning (e.g., processing nutrients, filtering toxins, regulating metabolism). Yet despite years of research and billions of dollars invested across the industry, therapies capable of actively reversing fibrosis remain elusive.
Now, under this new strategic collaboration, Engitix will use its proprietary extracellular matrix (ECM) platform to identify potential drug targets associated with fibrosis resolution. The ECM can be thought of as the biological scaffolding that surrounds cells. It provides structural support, but it also contains important signals that influence how tissues behave, heal and respond to disease. While many drug discovery programs focus primarily on cells themselves, Engitix has built its platform around understanding this surrounding environment and the information it contains.
The company will generate human tissue-based disease models and datasets designed to uncover biological signals linked to recovery from fibrosis. GSK will then have the option to license the resulting assays, datasets and targets, and will lead any further development and commercialization efforts.
The financial terms reflect the scale of the opportunity. Engitix is eligible to receive up to $60 million (£44.5 million) in upfront and near-term payments, alongside potential milestone payments of up to $159 million (£118 million) per target, plus royalties on future product sales.
One reason fibrosis drug development has proven so difficult is that promising results in laboratory models frequently fail to translate into human patients. Increasingly, biotech companies are attempting to close that gap by generating data directly from human tissues and disease systems rather than relying exclusively on traditional preclinical approaches. This trend is becoming one of the most important shifts in drug discovery. The goal is simple: understand disease as it actually exists in people.
As Dr Giuseppe Mazza, cofounder and CEO of Engitix, explained, the collaboration “is very significant for Engitix and highlights the unique capability of our ECM platform to capture the biology of fibrosis regression in human tissue.”
“We are excited to partner with GSK, given its strong presence and expertise in liver disease. By combining our human-centric disease models with GSK’s development capabilities, we aim to identify and validate high-confidence targets with the potential to transform treatment for liver fibrosis,” he added.
For GSK, the appeal lies in access to a different lens on disease biology. Dr Kaivan Khavandi, SVP, R&D Head Respiratory, Immunology & Inflammation (RI&I), and Head of Translational & Development Sciences at GSK, said the company is “excited to collaborate with Engitix to access their differentiated human biology platform.”
“The ability to combine functional assays with rich multi-omics datasets complements our internal capabilities and network of collaborations in this space, supporting our work to develop differentiated, fibrosis-targeted medicines for patients,” he added.
Although this announcement centers on liver disease, its implications may extend much further. Fibrosis is increasingly recognized as a common feature of aging. As tissues experience years of stress, injury and inflammation, scar tissue can gradually accumulate across multiple organs, contributing to declining function and reduced resilience. In that sense, fibrosis is also an aging problem. This is why researchers across the longevity field are paying attention to regenerative approaches that do more than slow deterioration.
The Engitix-GSK collaboration is still at the discovery stage, and many hurdles remain before any therapy reaches patients. However, we are moving from managing decline toward actively supporting repair.
And that brings the story back to Engitix’s mission. If the future of medicine lies in helping the body recover rather than simply endure disease, then understanding the biological architecture that governs healing could become one of the most important challenges in healthcare – and one of the most consequential opportunities for longevity.
